Press coverage about Concert Pharmaceuticals (NASDAQ:CNCE) has been trending positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.963653427294 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

Several equities analysts have weighed in on the company. HC Wainwright assumed coverage on Concert Pharmaceuticals in a report on Monday, July 24th. They set a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. ValuEngine upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Aegis restated a “buy” rating and set a $25.00 target price on shares of Concert Pharmaceuticals in a report on Monday, June 12th. Finally, BidaskClub lowered Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $24.83.

Concert Pharmaceuticals (NASDAQ:CNCE) traded down 0.20% during trading on Wednesday, reaching $15.16. The company’s stock had a trading volume of 58,129 shares. The company’s 50 day moving average price is $14.59 and its 200 day moving average price is $14.62. The company’s market cap is $343.93 million. Concert Pharmaceuticals has a 52 week low of $7.11 and a 52 week high of $19.11.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.04. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.20 million. On average, equities analysts anticipate that Concert Pharmaceuticals will post ($2.18) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/06/favorable-media-coverage-somewhat-unlikely-to-impact-concert-pharmaceuticals-cnce-stock-price.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Insider Buying and Selling by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Stock Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.